In a study of 57 men who received oral CBD or placebo 90 minutes before participating in a fake public speech test, the researchers found that a dose of 300 mg CBD significantly reduced social anxiety during the test. Good quality systematic assessments identified only two small, unclear, risky studies of cannabinoids for the treatment of schizophrenia. These studies provide only limited evidence due to the risk of bias, short-term follow-up and evaluation of a single cannabinoid. In addition, the largest trial was designed to detect a moderate benefit of cannabidiol compared to antipsychotic amisulpride, but only took 60 percent of the planned sample. Therefore, it did not have the statistical power to detect minor or moderate differences between CBD and amisulpride. In general, the evidence is insufficient to determine whether cannabidiol is an effective treatment for individuals with schizophrenia or schizophreniform psychosis.
There are no test data related to the effects of cannabinoids on depressive disorders. We identified two systematic assessments of randomized studies evaluating the efficacy of cannabis or cannabinoids used as monotherapy or in addition to other therapies to reduce the frequency of seizures in people with epilepsy. Gloss and Vickrey published a systematic review of randomized controlled trials. They identified four reports of cannabinoid studies, all of which considered low quality. The main pre-specified result of the systematic review was the freedom of attack for 12 months or three times the longest previous epileptic interval.
The severity of the tic, assessed by multiple measurements, and overall clinical results were improved with THC capsules. These results were evaluated after 2 days (unclear risk of bias study) and after 6 weeks pickleball and cbd (high risk of bias study). None of the studies appropriately described randomization or concealment of the allocation and the 6-week trial was at high risk of bias in obtaining incomplete outcome data.
Most pain studies cited in Whiting et al. nabiximoles evaluated outside the United States. In its assessment, the Committee found that only a handful of studies have evaluated cannabis use in the United States, and that they have all reviewed floral cannabis supplied by the National Institute on Drug Abuse and evaporated or smoked. In contrast, many of the cannabis products sold on state-regulated markets are little like products available for federal-level research in the United States. For example, in 2015 in Colorado, 498,170 to 721,599 units of medicinal and recreational cannabis messages were sold monthly (Colorado DOR, 2016, p. 12). Pain patients also use current forms (p. E.g., transdermal spots and creams). Given the ubiquitous availability of cannabis products in much of the country, more research is needed into the different forms, routes of administration and combination of cannabinoids.
An overview of clinical studies on the effect of cannabinoids on sleep suggested that cannabinoids could improve sleep quality, reduce sleep disorders and reduce the time it takes to fall asleep. An evaluation and meta-analysis of 8 studies with evidence of low quality cannabis-based drugs found that they were better at reducing sleep problems compared to inactive drugs . The health benefits of CBD oil include reducing pain, treating epilepsy and potentially relieving anxiety.